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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A383presence of macrophages, especially in the lining layer, is associated
with progression of cartilage damage in OA, whereas synovial expres-
sion of MMPs seems related to progression regarding osteophyte for-
mation.
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Purpose: Synovium is mainly composed of synovial ﬁbroblast (SF) and
macrophage (SM) and a low percentage of other cell types. In osteo-
arthritis (OA) synovial inﬂammation is a key factor associated to pain
and symptoms and to a unique chemokine signature. Aim of the study
was to analyze the role of SF and SM in counteracting the effects due to
adipose stem cell co-culture.
Methods: Good manufacturing practice (GMP)-clinical grade ASC were
isolated from subcutaneous adipose tissue. Synoviocytes were isolated
from synovia of OA patients undergoing total joint replacement. Syn-
oviocytes both at passage 1 (p1) and 5 (p5) were characterized for the
following markers: CD3, CD14, CD16, CD45, CD68, CD90, vimentin,
VCAM-1 by ﬂow cytometry or immunocytochemistry. Secreted
inﬂammatory factors (IL6, CXCL8/IL8, CXCL1/GROa, CCL2/MCP-1, CCL3/
MIP1a, CCL5/RANTES, IL1b, TNFa) were analysed by multiplex bead-
based sandwich immunoassay or ELISA tests on synoviocytes p1 and p5
untreated or co-cultured with ASC in transwell. Macrophages type 1
(M1) and 2 (M2) were also isolated and co-cultured with ASC.
Results: Synoviocytes at p1 (mainly composed of SM and SF) were
approximately 1% positive to CD3, 8% to CD45,10% to CD14,12% to CD16,
8% to CD68, 90% to CD90 while synoviocytes at p.5 (only SF) were
negative to all the markers analyzed except for CD90. Moreover, syno-
viocytes at p. 1 produced a signiﬁcant higher amount of IL6, IL8/CXCL8,
CCL2/MCP-1, CCL3/MIP1a and CCL5/RANTES than at p.5, except CCL3/
MIP1a that was not detected. We conﬁrmed on serial sections of
synovial tissue that CCL3/MIP1a was a marker of SM since the same
cells were also positive to macrophages markers ( CD68, CD16). Inter-
estingly, we conﬁrmed that ASC reduced the release of inﬂammatory
factors only when cultured with p.1 synoviocytes. By contrast, ASC co-
cultured with p5 synoviocytes induced the release of all factors, except
CCL3/MIP1a that was still not released and expressed. Finally, we
demonstrated that ASC effects were strictly dependent by macrophages
type 1 and 2 that decreased the release of IL1b, TNFa and CCL3/
MIP1a.These effects were more evident when macrophages type 1 and
2 were co-cultured in contact.
Conclusions: These data demonstrate that the GMP-ASC effects on OA
synovial inﬂammation is strictly dependent by macrophages. ASC
counteracting effects are mainly mediated by both soluble factors and
cells cross talk.
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Purpose: The purpose of this study was to elucidate the alteration of
gene expression levels of matrix mettalloproteinases (MMPs), ADAMTS-
4 and interleukins (ILs) and protein production of PGE-2, IL-6, and IL-8
in cyclic biomechanical or biochemical stimulation of IL-1b to three-
dimensional cultured tissues of human synovium-derived cells and
further investigate the effects of NSAIDs, dexamethasone, and inhib-
ition of MyD88 using IL-1Ra on the biomechanical or biochemical
stimulation to three-dimensional cultured tissues.
Methods: Human synovium-derived cells were cultured in monolayer,
collected and then seeded to a mechanically reinforced collagen scaf-
fold to construct a three-dimensional cultured tissue. The three-
dimensional cultured tissues were stimulated either biomechanically orbiochemically using a cyclic loading bioreactor at 0.5Hz, 40kPa for 1
hour or 10 ng/ml of IL-1b. The mRNA expressions of MMP-1, MMP-3,
ADAMTS-4, ADMTS-5, IL-6, and IL-8 in the 3-D tissue were quantita-
tively determined by real time RT-PCR at 6 hours after mechanical
loading or IL-1b stimulation. The media were also assayed for protein
production of PGE2, IL-6, and IL-8 by HTRF®. mRNA expression and
protein production were also examined in the presence or absence of
various concentrations of NSAIDs of celecoxib (CEL), indomethacin
(IND) and etodolac (ETD), dexamethasone (DEX) from at a concen-
tration of 1.0 x 10-2 to that of 1.0 x 10 mM or 1mM of IL-1Ra.
Results: Both cyclic biomechanical stimulation and biochemical stim-
ulation of IL-1b statistically signiﬁcantly upregulated gene expressions
of MMP-1, -3, ADAMTS-4 and protein production of PGE2, IL-6 and -8 in
three-dimensional tissues of human synovium-derived cells. NSAIDs
and DEX statistically signiﬁcantly inhibited the upregulation of protein
expression of PGE2 by cyclic biomechanical loading or biochemical
stimulation of IL-1Ra. CEL had an inhibitory effect of upregulated gene
expression of ADAMTS-4 by biomechanical stimulation even at low
concentration of 1.0 x 10-2 mM, whereas IND did in relatively high dose
of 1.0 x 10-1 mM or more. ETD had no effects on ADAMTS-4 gene
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increased upregulated ADAMTS-4 gene expression by biomechanical
stimulation. Inhibition of MyD88 by IL-1Ra suppressed PGE2 pro-
duction at least partially in biomechanical stimulation and IL-1b
stimulation.
Conclusions: NSAIDs, DEX and MyD88 inhibition by IL-Ra suppressed
biomechanically or biochemically upregulated PGE2 production,
whereas IL-6 production was unchanged in NSAIDs, indicating the
possibility that mechanical stress could utilizes at least partially the IL-1
receptor signal transduction in the process of PGE2 production. Sup-
pression of ADAMTS-4 by CEL and relatively high dose of IND indicated
that these NSAIDs may have chondroprotective effect, while DEX which
further increased ADAMTS-4 gene expression after biomechanical
stimulation may imply the destructive effect of DEX by biomechanically
affected synovial joint.Therapy: Non-Pharmacologic
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Purpose: To investigate the efﬁcacy of low-level laser therapy (LLLT)
treatment of knee osteoarthritis (KOA) by carrying out a systematic
literature search followed by meta-analyses on selected studies.
Methods: MEDLINE, EMBASE, ISI Web of Science and Cochrane
Library databases were systematically searched from January 2000 to
November 2014. Studies were included if they were randomized
controlled trials (RCTs) , written in English, comparing LLLT with
sham laser in KOA patients diagnosed according to American College
of Rheumatology guidelines. Two independent reviewers assessed
study quality using the PEDro scale. Meta-analyses were performed
to get an indication of treatment efﬁcacy from the available pooled




Sample Size Age (y) Gender
(M/F)
BMI
Gur et al. 2003 DB-RCT Study Group (n¼30) 58.64 (5.92) 5/25 31.1
Control Group (n¼30) 60.52 (6.91) 6/24 30.2
Tascioglu et al. 2004 DB-RCT Study Group (n¼20) 62.86 (7.32) 6/14 27.5
Control Group (n¼20) 64.27 (10.55) 7/13 29.5
Yurtkuran et al. 2007 DB-RCT Study Group (n¼28) 51.83 (6.83) 1/27 31.7
Control Group (n¼27) 53.478 (7.13) 1/26 32.7
Alfredo et al. 2011 DB-RCT Study Group (n¼24) 61.15 (7.52) 5/15 30.1
Control Group (n¼22) 62.25 (6.87) 4/16 29.2
Fukuda et al. 2011 DB-RCT Study Group (n¼25) 63.0 (9.0) 5/20 30.0
Control Group (n¼22) 63.0 (8.0) 8/14 28.7
Alghadir et al. 2014 SB-RCT Study Group (n¼20) 55.2 (8.14) 10/10 32.3
Control Group (n¼20) 57 (7.77) 12/8 33.0
Kheshie et al. 2014 SB-RCT Study Group (n¼20) 56.56 (7.86) 20/0 28.6
Control Group (n¼20) 55.6(11.02) 20/0 28.5
Al Rashoud et al. 2014 DB-RCT Study Group (n¼26) 52 (9) 10/16 38.0
Control Group (n¼23) 56(11) 8/15 37.1
Hinman et al. 2014 DB-RCT Study Group (n¼71) 63.4(8.7) 43/28 30.7
Control Group (n¼70) 63.8 (7.5) 31/39 28.8
DB-RCT: Double blind-randomized controlled trial; SB-RCT: Single blind-randomized co
Mean (standard deviation) are provided above for age, BMI, pain and function
a N: Not conforming to WALT recommendations
b Y: Conforming to WALT recommendationsResults: Nine randomized controlled trials (7 double-blind, 2 single-
blind) met the criteria for inclusion (Table 1). Data of 518 patients were
extracted (264 patients in treated groups, 254 patients in control
groups, 58% female, mean age ranging from 51.83 to 64.27 years,
Kellgren-Lawrence grade2). The methodological quality of all inclu-
ded studies was high based on a PEDro score7. Seven trials provided
data on pain assessed by VAS scale right after therapy. The standardized
mean difference (SMD) in VAS pain score right after therapy was not
signiﬁcantly different between treated and control groups (SMD¼-0.28
[95% CI¼-0.66, 0.10], I-square¼66%)(Figure 1). Subgroup analysis based
on whether the studies were performed according to the World Asso-
ciation Laser Therapy (WALT) recommendations also failed to unmask
any signiﬁcant difference by laser treatment status (Figure 1). Moreover,
another subgroup analysis based on the severity of OA also did not
identify any signiﬁcant differences between the two groups (SMD -0.28,
95%CI -0.66, 0.10). Analysis of the pooled data from the ﬁve studies with
VAS pain data after 12 weeks of therapy also did not support the
superiority of LLLT over placebo at this timepoint. Similar results were
obtained when we analyzed the pooled data on WOMAC pain, stiffness
and function outcomes (5 and 3 studies had outcome data right after
and 12 weeks after therapy respectively).
Conclusions: Our ﬁndings indicate that the best available current evi-
dence, based on studies with sham laser control therapy, does not
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